Last reviewed · How we verify
Iron Dextran Injection
Iron Dextran Injection, marketed by Menoufia University, is an established treatment in the iron replacement therapy market. A key strength is the protection afforded by its composition patent, which is set to expire in 2028. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | Iron Dextran Injection |
|---|---|
| Also known as | Dexferrum and INFeD |
| Sponsor | Menoufia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
- Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient (PHASE3)
- Immune Response During the Conservative and Minimal Invasive Treatment of Pain Caused by Lumbar Disc Herniation (NA)
- Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma (PHASE4)
- A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants (PHASE3)
- A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants (PHASE3)
- A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants (PHASE2)
- A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |